ES2126145T3 - Redireccionamiento de anticuerpos. - Google Patents

Redireccionamiento de anticuerpos.

Info

Publication number
ES2126145T3
ES2126145T3 ES94926336T ES94926336T ES2126145T3 ES 2126145 T3 ES2126145 T3 ES 2126145T3 ES 94926336 T ES94926336 T ES 94926336T ES 94926336 T ES94926336 T ES 94926336T ES 2126145 T3 ES2126145 T3 ES 2126145T3
Authority
ES
Spain
Prior art keywords
linking
antibody
specificity
target
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926336T
Other languages
English (en)
Inventor
Gregory Paul Winter
Kaspar Philippe Holliger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319969A external-priority patent/GB9319969D0/en
Priority claimed from PCT/GB1993/002492 external-priority patent/WO1994013804A1/en
Priority claimed from GB9412166A external-priority patent/GB9412166D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2126145T3 publication Critical patent/ES2126145T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
    • C12N2310/1241—Tetrahymena
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LOS ANTICUERPOS SE REENCAMINAN A UN OBJETIVO PARA EL QUE NO TIENE UNA ESPECIFICIDAD FUNCIONAL BAJO CIRCUNSTANCIAS NORMALES. SE UTILIZA UNA SUSTANCIA DE ENLACE MULTIESPECIFICA QUE TIENE UNA ESPECIFICIDAD DE ENLACE PARA EL OBJETIVO Y UNA ESPECIFICIDAD DE ENLACE A ANTIANTICUERPOS. LA SUSTANCIA DE ENLACE PUEDE INCLUIR UNA REGION DE ENLACE DE ANTIGENOS DE LA INMUNOGLOBULINA Y PUEDE SER UN "DIACUERPO". DEPENDIENDO DEL ANTICUERPO QUE SE TRATE, SE SELECCIONAN FUNCIONES EFECTORAS TALES COMO COMPLEMENTO, ADCC Y BLOQUEO INMUNE PARA QUE ACTUEN EN EL OBJETIVO. EJEMPLOS DE OBJETIVOS SON LAS CELULAS HUMANAS. SE PRESENTAN EJEMPLOS DE UTILIZACION IN VIVO E IN VITRO, INCLUIDA LA LISIS DE CELULAS TUMORALES Y AGLUTINACION DE LOS HEMATIES DE LA SANGRE.
ES94926336T 1993-09-22 1994-09-16 Redireccionamiento de anticuerpos. Expired - Lifetime ES2126145T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939319969A GB9319969D0 (en) 1993-09-22 1993-09-22 Binding proteins iv
PCT/GB1993/002492 WO1994013804A1 (en) 1992-12-04 1993-12-03 Multivalent and multispecific binding proteins, their manufacture and use
GB9412166A GB9412166D0 (en) 1993-09-22 1994-06-17 Retargetting antibodies

Publications (1)

Publication Number Publication Date
ES2126145T3 true ES2126145T3 (es) 1999-03-16

Family

ID=26303591

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94926336T Expired - Lifetime ES2126145T3 (es) 1993-09-22 1994-09-16 Redireccionamiento de anticuerpos.

Country Status (9)

Country Link
US (1) US6589527B1 (es)
EP (1) EP0720624B1 (es)
JP (1) JPH09503759A (es)
AT (1) ATE173740T1 (es)
AU (1) AU680685B2 (es)
CA (1) CA2169620A1 (es)
DE (1) DE69414870T2 (es)
DK (1) DK0720624T3 (es)
ES (1) ES2126145T3 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK1276855T3 (da) * 2000-04-17 2012-11-26 Dyax Corp Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie
DK1360288T3 (da) 2000-12-18 2011-06-14 Dyax Corp Fokuserede biblioteker af genetiske pakker
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
WO2009132287A2 (en) 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
WO2011032181A2 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
CN106119189B (zh) * 2016-07-11 2020-04-10 山东亚大药业有限公司 胎儿有核红细胞的分离纯化方法及试剂盒
KR20210009421A (ko) 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US6329507B1 (en) 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse

Also Published As

Publication number Publication date
EP0720624B1 (en) 1998-11-25
DK0720624T3 (da) 1999-08-09
AU7621494A (en) 1995-04-10
ATE173740T1 (de) 1998-12-15
DE69414870T2 (de) 1999-05-12
CA2169620A1 (en) 1995-03-30
US6589527B1 (en) 2003-07-08
EP0720624A1 (en) 1996-07-10
JPH09503759A (ja) 1997-04-15
AU680685B2 (en) 1997-08-07
DE69414870D1 (de) 1999-01-07

Similar Documents

Publication Publication Date Title
ES2126145T3 (es) Redireccionamiento de anticuerpos.
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ATE125362T1 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
ATE171207T1 (de) Monoklonaler antikörper
ES2091438T3 (es) Anticuerpos recombinantes especificos para un receptor del factor de crecimiento.
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
ATE94205T1 (de) Monoklonale antikoerper gegen melanoma-assoziierte antigene, hybridzellinien, die diese antikoerper produzieren, und ihre verwendung.
ES2161751T3 (es) Anticuerpo monoclonal que se une especificamente al endotelio vascular tumoral y usos del mismo.
ATE129902T1 (de) Monoklonale antikörper gegen den bereich der leichten kette von menschlichem faktor xii sowie methoden zu deren herstellung und verwendung.
DE69126607D1 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
ES2110993T3 (es) Anticuerpos monoclonales especificos para la toxina b de clostridium difficile.
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DE69522689D1 (de) Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper
ES2051737T3 (es) Antigenos, anticuerpos y metodos para la identificacion de tumores humanos metastasicos, y lineas celulares para producir dichos anticuerpos.
MX9301500A (es) Anticuerpos construidos con ingenieria genetica
Hämmerling et al. Immunofluorescence analysis of Ig determinants of mouse thymocytes and T cells
ES2148283T3 (es) Gen merlin supresor de tumores y usos del mismo.
ES8800604A1 (es) Un metodo para producir anticuerpos monoclonales
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
ES8800981A1 (es) Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo
ES2180052T3 (es) Anticuerpos especificos del cancer de prostata para inmunodeteccion e inmunoterapia.
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
DE3855280D1 (de) Von mca 16-88 erkanntes antigen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 720624

Country of ref document: ES